HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBP seizes toothpaste

This article was originally published in The Rose Sheet

Executive Summary

U.S. Customs and Border Protection officers in Charleston, S.C. announce Oct. 3 they have seized 1,440 tubes of toothpaste adulterated with antifreeze ingredient diethylene glycol (DEG). CBP says the toothpaste has deceptive country-of-origin markings: Shrink-wrap on the outside of the boxes is marked "made in China" while the boxes themselves are marked "made in India." The agency says officers performed an initial examination of the shipment in July and sent samples to a lab where they tested positive for DEG. China has banned firms in the country from using DEG as a toothpaste ingredient after FDA discovered DEG in multiple Chinese-manufactured products and in June ordered the detention without physical examination of all dentifrice products containing DEG (1"The Rose Sheet" June 11, 2007, p. 8)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel